US2021253591A1PendingUtilityA1
Derivatives of porphyrins, their process of preparation and their use for treating viral infections
Est. expiryOct 30, 2035(~9.3 yrs left)· nominal 20-yr term from priority
A61K 31/00C07D 487/22A61P 31/18A61P 31/12A61K 31/555A61P 31/16A61P 31/00A61P 31/14A61P 31/20A61K 31/409A61P 31/22
65
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention concerns metallated porphyrin derivatives as ligands of G-quadruplex and their novel use as anti-viral agents.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . A compound of formula (IA):
wherein:
in Formula (IA) - - - represents an optionally present single bond;
M represents H 2 , Cobalt (Co), Manganese (Mn) or a Nickel (Ni) atom;
A − represents a counter anion; and
wherein - - - represents the attachment of X to the phenyl groups in Formula (IA).
2 . The compound according to claim 1 wherein X represents
and M represents a Manganese atom.
3 . The compound of formula (IA) according to claim 1 , wherein A − represents a halogen ion.
4 . The compound according to claim 1 , wherein A − is Cl − .
5 . A pharmaceutical composition comprising the compound according to claim 1 , and at least one pharmaceutically acceptable excipient.
6 . A process for the preparation of the compound according to claim 1 comprising reacting a compound of formula (II)
wherein X is defined as in claim 1 , and wherein B − represents a counter anion;
with a gold-containing complex.
7 . The process according to claim 6 wherein the counter anion is trifluoroacetate.
8 . The process according to claim 6 wherein the gold-containing complex is a complex of formula (III):
KAu III A 4 (III)
wherein A represents a counter anion.Join the waitlist — get patent alerts
Track US2021253591A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.